Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:APOP Cellect Biotechnology (APOP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Cellect Biotechnology Stock (NASDAQ:APOP) 30 days 90 days 365 days Advanced Chart Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Cellect Biotechnology alerts:Sign Up Key Stats Today's Range$13.10▼$13.3750-Day Range$7.54▼$13.4052-Week Range$6.64▼$35.52Volume17,400 shsAverage Volume479,845 shsMarket Capitalization$12.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.Read More… Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Receive APOP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellect Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address APOP Stock News HeadlinesPatent Term Adjustment and Double Patenting After In re CellectOctober 1, 2024 | reuters.comKrystal Biotech Inc.March 1, 2024 | wsj.comThe only candlestick pattern worth a darnIt’s widely known that 80% of daily market action is driven by Wall Street algorithms… Now, most people think of the algorithms are “bad” When in reality, they are neither good nor bad… They are simply programmed to buy and sell certain stocks over and over again… But here is the thing… They are predictable… They typically buy the same stocks at the same levels over and over again…November 17, 2024 | WealthPress (Ad)Raleigh/Durham Biotech NewsJune 23, 2023 | bizjournals.comSana Biotechnology Is Technically Overbought So Buy It LaterApril 19, 2023 | seekingalpha.comPiper Sandler says this biotech stock can outperform thanks to Alzheimer's treatmentApril 19, 2023 | cnbc.com$3M Bet On This Biotechnology Stock? Check Out These 3 Penny Stocks Insiders Are BuyingFebruary 23, 2023 | benzinga.comGlobal Agricultural Biotechnology Market to Reach $88.9 Billion by 2030January 30, 2023 | finance.yahoo.comSee More Headlines APOP Stock Analysis - Frequently Asked Questions How were Cellect Biotechnology's earnings last quarter? Cellect Biotechnology Ltd. (NASDAQ:APOP) posted its earnings results on Tuesday, November, 13th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.02. When did Cellect Biotechnology's stock split? Cellect Biotechnology's stock split on the morning of Tuesday, October 26th 2021. The 2-1 split was announced on Tuesday, October 26th 2021. The newly minted shares were issued to shareholders after the market closes on Tuesday, October 26th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. What other stocks do shareholders of Cellect Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cellect Biotechnology investors own include Elbit Systems (ESLT), Gilead Sciences (GILD), Protalix BioTherapeutics (PLX), Advanced Micro Devices (AMD), NVIDIA (NVDA), Acasti Pharma (ACST) and Corbus Pharmaceuticals (CRBP). Company Calendar Last Earnings11/13/2018Today11/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolNASDAQ:APOP CUSIPN/A CIK1671502 Webwww.cellect.co Phone(729) 974-1444Fax972-9767-8750Employees2,020Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.01 Quick Ratio3.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.77 per share Price / Book2.76Miscellaneous Outstanding Shares977,000Free FloatN/AMarket Cap$12.87 million OptionableNot Optionable Beta1.87 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:APOP) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellect Biotechnology Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellect Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
